2025-09-30
Congratulations! Shanghai Baiyang Pharmaceutical Technology Co., Ltd., a Subsidiary of Baiyang Pharmaceutical, Wins "2025 Shanghai Top 100 Growing Enterprises"
On September 23, 2025, institutions including the Shanghai Enterprise Confederation and the Shanghai Entrepreneurs Association jointly released a series of lists and development reports such as the 2025 Shanghai Top 100 Enterprises, Shanghai Top 100 Manufacturing Enterprises, and Shanghai Top 100 Growing Enterprises, revealing the latest status of Shanghai's economic development. Shanghai Baiyang Pharmaceutical Technology Co., Ltd. (formerly Shanghai Huanghai Pharmaceutical Co., Ltd.), a subsidiary of Shanghai Baiyang Pharmaceutical Co., Ltd. (referred to as "Baiyang Pharmaceutical"), successfully made it to the "2025 Shanghai Top 100 Growing Enterprises" list by virtue of its groundbreaking achievements in the modernization of traditional Chinese medicine (TCM) and high growth potential.

Shanghai Huanghai Pharmaceutical Co., Ltd., Ranked 47th in the 2025 Shanghai Top 100 Growing Enterprises, Issued by Shanghai Enterprise Confederation, Shanghai Entrepreneurs Association, and Jiefang Daily, September 2025]
Sponsored by the Shanghai Enterprise Confederation, the Shanghai Entrepreneurs Association, and other organizations, this series of lists has entered its 21st year in 2025. The lists conduct a comprehensive assessment of enterprises based on indicators such as operating revenue, net profit, total assets, total tax payment, and R&D expenses. They not only evaluate enterprises' profitability but also attach great importance to their development potential, demonstrating recognition of enterprises' strength. These lists have become a barometer of Shanghai's economic development and a weather vane for enterprise growth and development. As one of the most influential enterprise rankings in Shanghai, they have gained widespread attention and recognition from all sectors of society due to their objectivity, fairness, and authority.
As a TCM modernization R&D and production platform under Baiyang Pharmaceutical, Shanghai Baiyang Pharmaceutical Technology Co., Ltd. adheres to the modern TCM R&D and production concept of "diagnosable diseases, controllable quality, and verifiable efficacy". It focuses on making breakthroughs in the treatment of refractory diseases where there are unmet medical needs, and has launched a number of modern TCM products such as Fuzheng Huayu (a TCM preparation) and Qishe Pills. In terms of the production process, the company has built a digital production workshop for modern compound TCMs oriented to the international market, and insists on establishing a whole-industry-chain quality control system for TCMs in accordance with international standards to ensure the safety and efficacy of pharmaceuticals.
In the future, taking the award of its subsidiary as an opportunity, Baiyang Pharmaceutical will continue to uphold the tenet of "International Quality, Safeguarding Health", carry out in-depth cooperation with national-level scientific research institutions and universities, accelerate the innovation process of more high-end preparations, modern TCMs, and original research products, and develop and produce more innovative pharmaceuticals that can truly optimize medical scenarios and highlight China's original independent intellectual property rights, so as to continuously promote the high-quality development of the enterprise and the industry.
Related News